Drug Information

Drug General Information
Drug ID
D06JQS
Former ID
DIB015208
Drug Name
HuM195/rGel
Synonyms
HuM195/rGel, MD Anderson; Conjugated anti-CD33 antibodies (cancer), MD Anderson; HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics; HuM195/rGel (leukemia), Targa Therapeutics; Anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering; HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson; HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome); HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics; HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics
Drug Type
Antibody
Indication Leukemia [ICD9: 208.9; ICD10:C90-C95] Phase 1 [546349]
Company
Targa therapeutics
Target and Pathway
Target(s) Myeloid cell surface antigen CD33 Target Info [531997]
KEGG Pathway Hematopoietic cell lineage
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 546349Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007636)
Ref 531997Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.